On watch, $ANTH 0.742 -1.268 -63.08 18,013,006
Post# of 22755
Anthera Pharmaceuticals Inc. (ANTH) lost roughly two-thirds of its market value in late trading Tuesday after the company announced that one of its drugs had come up short in a study. Anthera said that the drug Sollpura, which is meant to help a specific kind of maldisgestion in cystic fibrosis patients, "narrowly missed" the primary endpoint for the study. The company said the structure of the study may have hindered the results by not allowing some patients to increase their dosage during the testing, and plans to initiate a new experiment in the first quarter of 2017. Anthera stock closed at $2.01 Tuesday, but fell to less than 70 cents in late trading.
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'